Limits...
MicroRNA Expression in Myocardial Tissue and Plasma of Patients with End-Stage Heart Failure during LVAD Support: Comparison of Continuous and Pulsatile Devices.

Lok SI, de Jonge N, van Kuik J, van Geffen AJ, Huibers MM, van der Weide P, Siera E, Winkens B, Doevendans PA, de Weger RA, da Costa Martins PA - PLoS ONE (2015)

Bottom Line: Our aim was to analyze cardiac miR expression patterns associated with each type of device, to analyze differences in the regulation of the induced cardiac changes.Circulating miR-21 decreased at 1, 3, and 6 months after LVAD implantation.However, the miR expression patterns do not seem to significantly differ between pf- and cf-LVAD implying that most cardiac changes or clinical outcomes specific to each device do not relate to differences in miR expression levels.

View Article: PubMed Central - PubMed

Affiliation: Department of Cardiology, University Medical Center, Utrecht, the Netherlands; Department of Pathology, University Medical Center, Utrecht, the Netherlands.

ABSTRACT

Aim: Pulsatile flow left ventricular assist devices (pf-LVADs) are being replaced by continuous flow LVADs (cf-LVADs) in patients with end-stage heart failure (HF). MicroRNAs (miRs) play an important role in the onset and progression of HF. Our aim was to analyze cardiac miR expression patterns associated with each type of device, to analyze differences in the regulation of the induced cardiac changes.

Methods and results: Twenty-six miRs were selected (based on micro-array data and literature studies) and validated in myocardial tissue before and after pf- (n = 17) and cf-LVAD (n = 17) support. Of these, 5 miRs displayed a similar expression pattern among the devices (miR-129*, miR-146a, miR-155, miR-221, miR-222), whereas others only changed significantly during pf-LVAD (miR-let-7i, miR-21, miR-378, miR-378*) or cf-LVAD support (miR-137). In addition, 4 miRs were investigated in plasma of cf-LVAD supported patients (n = 18) and healthy controls (n = 10). Circulating miR-21 decreased at 1, 3, and 6 months after LVAD implantation. MiR-146a, miR-221 and miR-222 showed a fluctuating time pattern post-LVAD.

Conclusion: Our data show a different miR expression pattern after LVAD support, suggesting that differentially expressed miRs are partially responsible for the cardiac morphological and functional changes observed after support. However, the miR expression patterns do not seem to significantly differ between pf- and cf-LVAD implying that most cardiac changes or clinical outcomes specific to each device do not relate to differences in miR expression levels.

No MeSH data available.


Related in: MedlinePlus

Device specific changes in miR expression.Selection of myocardial miRs that changed only in pulsatile flow (pf-LVAD) or continuous flow LVAD (cf- LVAD), respectively. During pf-LVAD support, miR-let-7i (a), miR-21 (b), miR-378 (c) and miR-378* (d) changed significantly post LVAD, whereas in cf-LVAD these miRs did not differ significantly. In cf-LVAD, only miR-137 (e) changed significantly post-LVAD. The asterisk (*) represents p<0.05.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4592005&req=5

pone.0136404.g002: Device specific changes in miR expression.Selection of myocardial miRs that changed only in pulsatile flow (pf-LVAD) or continuous flow LVAD (cf- LVAD), respectively. During pf-LVAD support, miR-let-7i (a), miR-21 (b), miR-378 (c) and miR-378* (d) changed significantly post LVAD, whereas in cf-LVAD these miRs did not differ significantly. In cf-LVAD, only miR-137 (e) changed significantly post-LVAD. The asterisk (*) represents p<0.05.

Mentions: Several miRs showed a significant change in either pf-LVAD or cf-LVAD support. Four miRs changed in expression after pf-LVAD (miR-let-7i, miR-21, miR-378 and miR-378*, Fig 2A–2D), whereas the expression of miR-137 only changed significantly during cf-LVAD support (Fig 2E). Of note, let-7i and miR-21 changed non-significantly in cf-LVAD tissue, but showed the same trend as in pf-LVAD. In fact, statistical analysis to investigate whether the difference in expression of these four microRNAs really differ between pf-LVAD and cf-LVAD support revealed that the effects were not significant when comparing the change pre- and post-LVAD within individuals (Fig B in S1 File). Interestingly, several miRs that have previously been reported to be differentially expressed between pre- and post pf-LVAD [7], did not significantly change in cf-LVAD. This was the case for miR-133a, miR-133b, miR-1, miR-151, miR-7a and miR-378 (Fig C in S1 File).


MicroRNA Expression in Myocardial Tissue and Plasma of Patients with End-Stage Heart Failure during LVAD Support: Comparison of Continuous and Pulsatile Devices.

Lok SI, de Jonge N, van Kuik J, van Geffen AJ, Huibers MM, van der Weide P, Siera E, Winkens B, Doevendans PA, de Weger RA, da Costa Martins PA - PLoS ONE (2015)

Device specific changes in miR expression.Selection of myocardial miRs that changed only in pulsatile flow (pf-LVAD) or continuous flow LVAD (cf- LVAD), respectively. During pf-LVAD support, miR-let-7i (a), miR-21 (b), miR-378 (c) and miR-378* (d) changed significantly post LVAD, whereas in cf-LVAD these miRs did not differ significantly. In cf-LVAD, only miR-137 (e) changed significantly post-LVAD. The asterisk (*) represents p<0.05.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4592005&req=5

pone.0136404.g002: Device specific changes in miR expression.Selection of myocardial miRs that changed only in pulsatile flow (pf-LVAD) or continuous flow LVAD (cf- LVAD), respectively. During pf-LVAD support, miR-let-7i (a), miR-21 (b), miR-378 (c) and miR-378* (d) changed significantly post LVAD, whereas in cf-LVAD these miRs did not differ significantly. In cf-LVAD, only miR-137 (e) changed significantly post-LVAD. The asterisk (*) represents p<0.05.
Mentions: Several miRs showed a significant change in either pf-LVAD or cf-LVAD support. Four miRs changed in expression after pf-LVAD (miR-let-7i, miR-21, miR-378 and miR-378*, Fig 2A–2D), whereas the expression of miR-137 only changed significantly during cf-LVAD support (Fig 2E). Of note, let-7i and miR-21 changed non-significantly in cf-LVAD tissue, but showed the same trend as in pf-LVAD. In fact, statistical analysis to investigate whether the difference in expression of these four microRNAs really differ between pf-LVAD and cf-LVAD support revealed that the effects were not significant when comparing the change pre- and post-LVAD within individuals (Fig B in S1 File). Interestingly, several miRs that have previously been reported to be differentially expressed between pre- and post pf-LVAD [7], did not significantly change in cf-LVAD. This was the case for miR-133a, miR-133b, miR-1, miR-151, miR-7a and miR-378 (Fig C in S1 File).

Bottom Line: Our aim was to analyze cardiac miR expression patterns associated with each type of device, to analyze differences in the regulation of the induced cardiac changes.Circulating miR-21 decreased at 1, 3, and 6 months after LVAD implantation.However, the miR expression patterns do not seem to significantly differ between pf- and cf-LVAD implying that most cardiac changes or clinical outcomes specific to each device do not relate to differences in miR expression levels.

View Article: PubMed Central - PubMed

Affiliation: Department of Cardiology, University Medical Center, Utrecht, the Netherlands; Department of Pathology, University Medical Center, Utrecht, the Netherlands.

ABSTRACT

Aim: Pulsatile flow left ventricular assist devices (pf-LVADs) are being replaced by continuous flow LVADs (cf-LVADs) in patients with end-stage heart failure (HF). MicroRNAs (miRs) play an important role in the onset and progression of HF. Our aim was to analyze cardiac miR expression patterns associated with each type of device, to analyze differences in the regulation of the induced cardiac changes.

Methods and results: Twenty-six miRs were selected (based on micro-array data and literature studies) and validated in myocardial tissue before and after pf- (n = 17) and cf-LVAD (n = 17) support. Of these, 5 miRs displayed a similar expression pattern among the devices (miR-129*, miR-146a, miR-155, miR-221, miR-222), whereas others only changed significantly during pf-LVAD (miR-let-7i, miR-21, miR-378, miR-378*) or cf-LVAD support (miR-137). In addition, 4 miRs were investigated in plasma of cf-LVAD supported patients (n = 18) and healthy controls (n = 10). Circulating miR-21 decreased at 1, 3, and 6 months after LVAD implantation. MiR-146a, miR-221 and miR-222 showed a fluctuating time pattern post-LVAD.

Conclusion: Our data show a different miR expression pattern after LVAD support, suggesting that differentially expressed miRs are partially responsible for the cardiac morphological and functional changes observed after support. However, the miR expression patterns do not seem to significantly differ between pf- and cf-LVAD implying that most cardiac changes or clinical outcomes specific to each device do not relate to differences in miR expression levels.

No MeSH data available.


Related in: MedlinePlus